Biotech Ideas

[gfp927z]

Dew - Apellis Pharma - >>> APLS’ Syfovre has_impressive_first_month—contrary to my skepticism about the drug’s efficacy:

https://www.globenewswire.com/news-release/2023/05/04/2662038/0/en/Apellis-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results.html

APLS sold $18.4M of Syfovre during March (the commercial launch was 3/1/23). Some of this may be a stocking bolus by medical practices.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171843665


<<<


>>> Apellis Pharmaceuticals, Inc. (APLS), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and -

SYFOVRE for treating geographic atrophy (GA). The company also develops -

APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA;

APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases;

and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver.

It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

<<<


https://finance.yahoo.com/quote/APLS/profile?p=APLS


---